Sustained Maintenance of Normal Insulin-like Growth Factor-I during Pregnancy and Successful Delivery in an Acromegalic Patient with Octreotide-LAR Treatment
نویسندگان
چکیده
Received: 26 November 2009, Accepted: 6 February 2010 Corresponding author: Kwang-Won Kim Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea Tel: +82-2-3410-3430, Fax: +82-2-3410-6956, E-mail: [email protected] Sustained Maintenance of Normal Insulin-like Growth Factor-I during Pregnancy and Successful Delivery in an Acromegalic Patient with Octreotide-LAR Treatment
منابع مشابه
Slow-release lanreotide and octreotide LAR in the medical therapy of acromegaly.
The first line of treatment for active acromegaly is still neurosurgery followed by radiotherapy. Octreotide (1), slow-release (SR) lanreotide (2) and octreotide LAR (3) are currently administered before surgery or in patients in whom surgery and/or radiotherapy have failed to restore normal growth hormone (GH)/insulin-like growth factor-I (IGF-I) levels. Cozzi et al. (4) have recently shown th...
متن کاملEffects of two different somatostatin analogs on glucose tolerance in acromegaly.
Impaired glucose tolerance is present in many acromegalic patients and treatment with somatostatin analogs has variable effects on glycemic control. The aim of this study was to compare the effects of 2 somatostatin analogs on glucose metabolism, lanreotide slow release (L-SR) and octreotide long acting release (O-LAR), in 10 patients with acromegaly (2 of whom with overt Type 2 diabetes mellit...
متن کاملExpression of somatostatin receptor SST4 in human placenta and absence of octreotide effect on human placental growth hormone concentration during pregnancy.
In pregnancy, the human placenta GH acts as a growth-promoting hormone and appears to be the main stimulator of insulin-like growth factor I (IGF-I) secretion. In a woman with a TSH-secreting macroadenoma, successful treatment with the somatostatin analog octreotide was conducted during the first month and the second half of pregnancy without side-effects on placental and fetal development. As ...
متن کاملSomatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly.
UNLABELLED We present two acromegalic patients in which clinical and molecular data are discussed in regard to their ability to predict long term octreotide LAR therapy response. CASE REPORTS Patient 1: female, 36 years old at diagnosis. Basal GH and IGF-I at diagnosis were 133 ng/mL and 181% above the upper limit of reference values (ULRV), respectively. Growth hormone during acute test with...
متن کاملAcromegalic gigantism with low serum level of growth hormone and elevated serum insulin-like growth factor-I.
In a case of acromegalic gigantism with hyperprolactinemia is reported, the basal serum growth hormone (GH) levels ranged from 1.2 to 1.9 ng/ml. Serum GH response to either insulin-induced hypoglycemia or GH-releasing hormone was blunted. Frequent blood sampling showed non-pulsatile GH secretion. Serum prolactin and insulin-like growth factor-I (IGF-I) levels were elevated. After unsuccessful s...
متن کامل